Publications by authors named "Suzanne Bonington"
Pre-treatment tumour perfusion parameters and initial RECIST response do not predict long-term survival outcomes for patients with head and neck squamous cell carcinoma treated with induction chemotherapy.
PLoS One
July 2018
Objectives: Previously, we showed that pre-treatment tumour plasma perfusion (Fp) predicts RECIST response to induction chemotherapy (ICT) in locoregionally advanced head and neck squamous cell carcinoma (HNSCC). The aim here was to determine whether the pre-treatment tumour Fp estimate, changes in tumour Fp or RECIST response post 2 cycles of ICT were prognostic for long-term survival outcomes.
Methods: A prospective study enrolled patients with high stage HNSCC treated with docetaxel (T), cisplatin (P) and 5-fluorouracil (F) (ICT) followed by synchronous cisplatin and intensity modulated radiotherapy.
Objectives: Non-response to induction chemotherapy (IC) occurs in 30% of head and neck squamous cell carcinoma (HNSCC) and has been predicted by tumor plasma flow (Fp) derived by perfusion computed tomography. The present study was designed to test whether baseline tumor Fp determined by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) would predict IC response.
Materials And Methods: A prospective open study powered to test the relationship between tumor Fp and response to IC (docetaxel, cisplatin, 5-fluorouracil) enrolled 50 patients with stage IV HNSCC.
Article Synopsis
- - The study investigates the use of sorafenib, a multikinase inhibitor, to treat advanced adenoid cystic carcinoma (ACC), which has poor chemotherapy response rates and limited success with targeted agents.
- - In a phase II trial, 23 patients were treated daily with sorafenib, resulting in median progression-free survival of 11.3 months and overall survival of 19.6 months, with 6-month and 12-month PFS rates of 69.3% and 46.2%.
- - Sorafenib was found to have modest effectiveness in ACC but was associated with significant side effects, leading to the conclusion that it is not recommended for further evaluation based on its limited benefits and high toxicity.
Introduction: Treatment of muscle-invasive bladder cancer with chemotherapy results in haemorrhagic inflammation, mimicking residual tumour on conventional MR images and making interpretation difficult. The aim of this study was to use dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to estimate descriptive and tracer kinetic parameters post-neoadjuvant chemotherapy and to investigate whether parameters differed in areas of residual tumour and chemotherapy-induced haemorrhagic inflammation (treatment effect, Tr-Eff).
Methods And Materials: Twenty-one patients underwent DCE-MRI scans with 2.
Purpose: To analyze, in a pilot study, rapidly acquired dynamic contrast-enhanced (DCE)-MRI data with a general two-compartment exchange tracer kinetic model and correlate parameters obtained with measurements of hypoxia and vascular endothelial growth factor (VEGF) expression in patients with squamous cell carcinoma of the head and neck.
Methods And Materials: Eight patients were scanned before surgery. The DCE-MRI data were acquired with 1.